
Vertex Pharmaceuticals (VRTX) · Biotechnology
Vertex Pharmaceuticals Q2 2026 earnings: summary, key numbers & outlook
Results filed 3 Aug 2026 · Quarter ended 30 Jun 2026
Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
Vertex added rare endocrine disease as a fifth pillar by agreeing to acquire Crinetics, while ALYFTREK, CASGEVY and JOURNAVX broadened its commercial base beyond TRIKAFTA.
Vertex's newer medicines gained ground. ALYFTREK is now reimbursed in 25 countries, and new Phase 3 data in children aged 2 to 5 support regulatory filings. The FDA approved CASGEVY for children 2 and older, which may make about 5,500 more patients eligible. JOURNAVX filled about 535,000 prescriptions in the quarter and gained Medicare Part D coverage at two more major PBMs.
Management is diversifying beyond cystic fibrosis. The pending Crinetics acquisition would add rare endocrine disease as a fifth pillar, and povetacicept faces a November 30, 2026 FDA decision in IgAN as the first step in a nephrology pillar. The tension is execution. Vertex must close the deal in the third quarter, launch new products, and keep a large pipeline on schedule while updating guidance after closing.
No call transcript for this quarter, so this summary also draws on: The Motley Fool ↗.
Key numbers
- Total revenue · GAAP
- $3.33 billion
- Net income · GAAP
- $1.1 billion
- Diluted EPS · GAAP
- $4.31
- Diluted EPS · non-GAAP
- $4.73
- Operating income · GAAP
- $1.2B
up 12% from the second quarter of 2025
compared to $1.0 billion in the second quarter of 2025
up from $3.99 a year ago
up from $4.52 a year ago
up from $1,151.1 a year ago
| Segment or metric | Value | Change |
|---|---|---|
| TRIKAFTA/KAFTRIO | $2.5B | down from $2,551.1 a year ago |
| ALYFTREK | $573.6M | up from $156.8 a year ago |
| CASGEVY | $76 million | 78% sequential growth and 151% growth from the second quarter of 2025 |
| JOURNAVX | $50 million | 71% sequential growth; more than quadrupled from $12 million a year ago |
| JOURNAVX prescriptions filled | approximately 535,000 | approximately 900,000 in the first six months of 2026 |
Where each number comes from
- Total revenue: “Total revenue increased 12% to $3.33 billion compared to the second quarter of 2025, primarily driven by the continued performance of cystic fibrosis (CF) therapies”
- Net income: “GAAP and non-GAAP net income were $1.1 billion and $1.2 billion, respectively, compared to $1.0 billion and $1.2 billion, respectively, for the second quarter of 2025”
- Diluted EPS: “Net income per diluted common share: GAAP | $4.31 | $3.99 | $8.33 | $6.48 Non-GAAP | $4.73 | $4.52 | $9.21 | $8.58”
- Diluted EPS: “Net income per diluted common share: GAAP | $4.31 | $3.99 | $8.33 | $6.48 Non-GAAP | $4.73 | $4.52 | $9.21 | $8.58”
- Operating income: “GAAP operating income | $1,246.9 | $1,151.1 | $2,385.0 | $1,781.2 Stock-based compensation expense | 170.2 | 167.3 | 336.6 | 333.4”
- TRIKAFTA/KAFTRIO: “TRIKAFTA/KAFTRIO | $2,497.2 | $2,551.1 | $4,851.9 | $5,086.6 ALYFTREK | 573.6 | 156.8 | 998.0 | 210.7”
- ALYFTREK: “ALYFTREK | 573.6 | 156.8 | 998.0 | 210.7 Other CF product revenues (1) | 137.1 | 193.7 | 273.0 | 349.0”
- CASGEVY: “second quarter 2026 CASGEVY revenue of $76 million, representing 78% quarter-over-quarter sequential growth and 151% growth compared to the second quarter of 2025”
- JOURNAVX: “second quarter 2026 JOURNAVX revenue of $50 million, representing 71% quarter-over-quarter sequential growth and more than quadrupling compared to $12 million in the second quarter of 2025”
- JOURNAVX prescriptions filled: “In the second quarter and first six months of 2026, approximately 535,000 and approximately 900,000 prescriptions, respectively, have been filled for JOURNAVX across the hospital and retail settings.”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q2 2026 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $3.3B | +12.5% | +11.6% |
| Operating income | $1.2B | +8.3% | +9.6% |
| Net income | $1.1B | +6.5% | +6.6% |
| Diluted EPS | $4.31 | +8.0% | +7.2% |
| Free cash flow | $1.0B | +9.3% | −21.7% |
| Operating margin | 37.4% | −1.4 pts | −0.7 pts |
Calculated by code from XBRL, not by the model.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Total revenue | full year 2026 | $13.1 billion to $13.2 billion |
| Non-CF product revenue | full year 2026 | $500 million or more |
| Combined GAAP R&D, AIPR&D and SG&A expenses | full year 2026 | $6.3 billion to $6.45 billion |
| Combined non-GAAP R&D, AIPR&D and SG&A expenses | full year 2026 | $5.65 billion to $5.75 billion |
| Non-GAAP effective tax rate | full year 2026 | 19.5% to 20.5% |
Key takeaways
Crinetics deal adds rare endocrine as fifth pillar
Vertex agreed to buy Crinetics for $85.00 per share in cash, about $8.8 billion net of cash acquired, with closing expected in the third quarter of 2026. Its guidance excludes the deal and will be updated after closing.
ALYFTREK is displacing TRIKAFTA in cystic fibrosis
ALYFTREK reimbursement reached 25 countries after four additions in the quarter, and Phase 3 data in children 2 to 5 led to global submissions. Vertex also signed a letter of intent with the Pan-Canadian Pharmaceutical Alliance for patients 6 and older.
CASGEVY expands to children as access widens
The FDA approved CASGEVY for ages 2 and older, 53 days after filing, and Germany granted reimbursement for patients 12 and older. CASGEVY is approved in 39 countries, and gentler conditioning programs aim to broaden eligibility further.
Povetacicept sets up Vertex's nephrology launch
The FDA accepted the IgAN accelerated-approval BLA with a PDUFA date of November 30, 2026. Vertex is also running Phase 3 work in primary membranous nephropathy and a Phase 2 study in generalized myasthenia gravis.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $2.9B * |
| Q1 2025 | $2.8B |
| Q2 2025 | $3.0B |
| Q3 2025 | $3.1B |
| Q4 2025 | $3.2B * |
| Q1 2026 | $3.0B |
| Q2 2026 | $3.3B |
| Q3 2026 | $3.4B |
Data
| Q1 2025 | $2.49 |
| Q2 2025 | $3.99 |
| Q3 2025 | $4.20 |
| Q1 2026 | $4.02 |
| Q2 2026 | $4.31 |
| Q3 2026 | $2.56 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 35.2% |
| Q1 2025 | 22.7% |
| Q2 2025 | 38.8% |
| Q3 2025 | 38.6% |
| Q4 2025 | 37.8% |
| Q1 2026 | 38.1% |
| Q2 2026 | 37.4% |
| Q3 2026 | 20.7% |
Data
| Q4 2024 | $492.0M |
| Q1 2025 | $778.2M |
| Q2 2025 | $927.4M |
| Q3 2025 | $1.1B |
| Q4 2025 | $348.6M |
| Q1 2026 | $1.3B |
| Q2 2026 | $1.0B |
| Q3 2026 | $545.8M |
Operating cash flow minus capital expenditure, from cash flow statements.
Questions
What is Vertex buying from Crinetics, and when will it close?
Vertex agreed to acquire Crinetics for $85.00 per share in cash, about $10.0 billion in equity value or $8.8 billion net of cash acquired, adding rare endocrine diseases as a fifth pillar. Closing is expected in the third quarter of 2026, and Vertex will update guidance afterward.
How are Vertex's newer CF medicine and non-CF products performing?
ALYFTREK is now reimbursed in 25 countries and drove new CF patient initiations. CASGEVY and JOURNAVX are growing from small bases, and Vertex expects $500 million or more in 2026 revenue from the two combined.
What is the status of povetacicept?
The FDA accepted the BLA for accelerated approval in IgAN with a PDUFA date of November 30, 2026. Vertex has also confirmed the Phase 3 dose in primary membranous nephropathy and is enrolling a Phase 2 study in generalized myasthenia gravis.
What key pipeline readouts is Vertex expecting?
Vertex expects VX-828 and VX-670 results in the second half of 2026 and AMPLIFIED data this fall. AMPLITUDE interim data in AMKD are due in early 2027, and updated timelines for the zimislecel and VX-017 diabetes programs are expected later this year.
Documents
SEC filing